We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > reSET-O

News List

FDA approves first prescription mobile app for opioid use disorder, courtesy of Sandoz and Pear Therapeutics pharmafile
December 12, 2018
A digital therapeutic launched by Pear Therapeutics and Novartis’ generics and biosimilars division Sandoz has become the first FDA-approved app of its kind for use in the treatment of opioid use disorder (OUD), it has emerged.
FDA clears Sandoz, Pear Therapeutics' prescription digital therapeutic for opioid use disorder firstwordpharma
December 11, 2018
Novartis' Sandoz unit and Pear Therapeutics announced Monday that the FDA cleared reSET-O, marking the first FDA-cleared prescription digital therapeutic for patients with opioid use disorder.